Trident Royalties lowers cost of capital ahead of a busy 2024. Watch the full video here.
“there is more than a one in four chance in the next decade of another global pandemic. We don’t know whether this will be influenza, a coronavirus, or something completely new. The #WHO refers to this unknown future threat as 'Disease X'.”
From the gaffa at Hemo - could we be getting an update on CBR soon !!
Shame we finished in the red - maybe it’s due to MMs spread that’s been particularly rather high in the last few sessions- if they know - they know !! - is it right the way they operate ? Let me know.
Better to have a discussion on a subject rather than speculation on Hemo CH.
Just found this
https://t.co/PMX1no5Yg4
Just a polite reminder - USA are still on holiday - so we will not hear anything today - this was also confirmed at the AGM - HEMO also said at the AGM
‘We believe in what we are doing ‘(1452hrs)
‘The company is focused on CAR-T ‘(1501hrs)
Just checked what my shares are worth
FC.k all really
Shouldnt be allowed to do what they did......
Well well well - what i thought was a good investment -
ALL GONE down the drain -
This business could have made millions
Hi - Maybe a silly question but as shareholders - how do we find out about any progress being made by the company and how is the investment we made doing ?
Nothing on the website ........
Quote from TMS earlier today -👍👌👏
HEMO says: ‘When fully developed, we would be able to create front-line treatments that may prevent the development of the next pandemic. Moreover, these new therapeutic tools can be used to protect against bio-terrorism, potentially rendering a universe of viral bio-weapons ineffective.’ A big claim: but the company’s belief in the significance and broad applicability of the proprietary technology led it to file a seminal provisional patent application last year.
Word for word fact from RNS…….let’s keep it real folks
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are confident that we will be able to address the FDA's questions and concerns regarding the IND. AML has poor survival rates and we are eager to resolve this hold and continue down the treatment development pathway toward saving lives."